An experimental heart failure drug developed by Novartis shows potential to become a blockbuster drug. In a trial, LCZ696 has reduced cardiovascular-related deaths by 20 percent compared with an older drug.
Novartis drug LCZ696 for treating heart failure, promises to be a blockbuster
Tech Times - 2 Sep 2014 15:40
An experimental heart failure drug developed by Novartis shows potential to become a blockbuster drug. In a trial, LCZ696 has reduced cardiovascular-related deaths by 20 percent compared with an older drug.
Share this Article
Recommended